Financials data is unavailable for this security.
View more
Year on year PRISM BioLab Co Ltd had net income fall 99.18% from a loss of 526.91m to a larger loss of 1.05bn despite a 170.64% increase in revenues from 112.93m to 305.62m. An increase in the selling, general and administrative costs as a percentage of sales from 210.83% to 308.53% was a component in the falling net income despite rising revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -- |
| Operating margin | -- |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in JPYView more
In 2024, PRISM BioLab Co Ltd increased its cash reserves by 287.32%, or 3.26bn. Cash Flow from Financing totalled 3.37bn or 1,102.69% of revenues. In addition the company generated 150.14m in cash from operations while cash used for investing totalled 244.19m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 58.79 |
|---|---|
| Tangible book value per share | 58.79 |
More ▼
Balance sheet in JPYView more
| Current ratio | 2.81 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in JPY
Year on year, growth in earnings per share excluding extraordinary items dropped -822.18%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
